Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arcutis Biotherapeutics, Inc.

< Previous 1 2 3 Next >
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Appoints David Topper as Chief Financial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Pricing of $150 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis to Report Third Quarter 2023 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Pricing of $100 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARQT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback